Tyrosine kinase inhibitors targeting MET exon 14 skipping alterations | Download Table
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Lung cancer with MET exon 14 skipping mutation | LCTT
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
metexon14 - Twitter Search / Twitter
i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. - Abstract - Europe PMC
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Lung cancer with MET exon 14 skipping mutation | LCTT
Progression-free survival by MET exon 14 alteration detection in... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Request PDF
Cancers | Free Full-Text | Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer | HTML
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
NSCLC with MET exon 14 skipping Treatment Approved | Lung Cancer Foundation of America
FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC - Lung Cancer Research Foundation
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy - Cheng - 2021 - MedComm - Wiley Online Library
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy
